Endocrine Abstracts

Background: As per 2014 Endocrine Society guidelines, 131I-MIBG therapy is usually reserved for metastatic or unresectable disease in patients with pheochromocytoma / paraganglioma. In this series, we describe three patients effectively treated with primary 131I-MIBG therapy. The indications were primary neo-adjuvant therapy prior to surgery, or palliative.Case series: Case 1 – 18-year-old male with a 60 mm para-aortic paragang...

(1) 30-year-old woman presenting at 34 weeks of pregnancy with symptoms of persisting headaches, diplopia and nausea. She presented again 4 years later with similar symptoms in a subsequent pregnancy at 35 weeks with additional complaints of blurred peripheral vision. (2) During her first pregnancy biochemistry revealed marked prolactin elevation (14,000 mIU/l). A non-contrast MRI scan of the pituitary revealed significant enlargement of the gland (22 x 14.4 x 12.5mm) bey...

Case history: Herein, we report the case of a 79-year-old male who presented acutely to A&E with recurrent episodes of symptomatic hypoglycaemia. A random glucose at presentation was low at 1.4 mmol/l and upon correction symptoms resolved. While hospitalized, he continued having episodes of symptomatic hypoglycaemia, requiring treatment with intravenous dextrose and per os steroids. Once stable, he was discharged with advice.Investigations: ...

There is limited research into the impact of active brown adipose tissue (aBAT) in patients with phaeochromocytomas and paragangliomas (PPGLs). A small body of evidence has shown that patients with PPGL patients can exhibit a high prevalence for aBAT recognized as ranging between 8 - 28% without specific correlation to germline mutations. Furthermore, it has been suggested that aBAT may be linked to increased mortality. Systematic searches of the Medical Literature Analysis an...